Aflibercept versus placebo in combination with docetaxel/prednisone for first-line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): Results from the multinational phase III trial (VENICE)

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2013
This article has no abstract
Epistemonikos ID: 97c6d660df3f75263451064f934364435738d562
First added on: Feb 05, 2025